Targets › APH1A
3 programs from 3 companies in 11 trials: 5 Phase 1, 5 Phase 2, 1 Phase 4; Oncology; next expected readout Mar 2027.
Non-catalytic subunit of the gamma-secretase complex, an endoprotease complex that catalyzes the intramembrane cleavage of integral membrane proteins such as Notch receptors and APP (amyloid-beta precursor protein). Required for normal gamma-secretase assembly. (UniProt, Q96BI3)
Open in Phaseline: the race on APH1A, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany | Nirogacestat Gamma-secretase inhibitor | APH1A, PSENEN, APH1B, PSEN1, NCSTN | Phase 4 | Desmoid Tumor | May 2027 |
| Children's Oncology Group | Nirogacestat Hydrobromide Gamma-secretase inhibitor | APH1A, PSENEN, APH1B, PSEN1, NCSTN | Phase 2 | Desmoid Fibromatosis | Dec 2032 |
| GSK | Nirogacestat Gamma-secretase inhibitor | APH1A, PSENEN, APH1B, PSEN1, NCSTN | Phase 1 | Multiple Myeloma; Tumor; Desmoid Tumor; AIDS-Related Kaposi Sarcoma | Mar 2027 |
Multiple Myeloma (5) Desmoid Tumor (3) Tumor (1) AIDS-Related Kaposi Sarcoma (1) Desmoid Fibromatosis (1)
small molecule (2), mixed (1)
GSK (1) SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany (1) Children's Oncology Group (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.